[go: up one dir, main page]

WO2014195849A3 - Composition et méthodes de traitement de maladies cérébrovasculaires - Google Patents

Composition et méthodes de traitement de maladies cérébrovasculaires Download PDF

Info

Publication number
WO2014195849A3
WO2014195849A3 PCT/IB2014/061892 IB2014061892W WO2014195849A3 WO 2014195849 A3 WO2014195849 A3 WO 2014195849A3 IB 2014061892 W IB2014061892 W IB 2014061892W WO 2014195849 A3 WO2014195849 A3 WO 2014195849A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
treatment
compositions
cerebral
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2014/061892
Other languages
English (en)
Other versions
WO2014195849A2 (fr
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of WO2014195849A2 publication Critical patent/WO2014195849A2/fr
Publication of WO2014195849A3 publication Critical patent/WO2014195849A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés représentés par les formules (I), (II) et (III) ou leurs sels pharmaceutiquement acceptables, ainsi que leurs polymorphes, solvates, énantiomères, stéréoisomères et hydrates. Les compositions pharmaceutiques comprenant une quantité efficace de composés de formule I, de formule II ou de formule III, et les méthodes de traitement de maladies cérébrovasculaires peuvent être formulées pour une administration orale, buccale, rectale, topique, transdermique, transmucosale, intraveineuse et parentérale, par sirop ou par injection. Ces compositions peuvent être utilisées pour le traitement de troubles aigus et chroniques cérébraux, métaboliques et vasculaires (artériosclérose cérébrale, thrombose et embolie cérébrales, accident ischémique transitoire).
PCT/IB2014/061892 2013-06-03 2014-06-02 Composition et méthodes de traitement de maladies cérébrovasculaires Ceased WO2014195849A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2432CH2013 2013-06-03
IN2432/CHE/2013 2013-06-03

Publications (2)

Publication Number Publication Date
WO2014195849A2 WO2014195849A2 (fr) 2014-12-11
WO2014195849A3 true WO2014195849A3 (fr) 2015-07-30

Family

ID=52008663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/061892 Ceased WO2014195849A2 (fr) 2013-06-03 2014-06-02 Composition et méthodes de traitement de maladies cérébrovasculaires

Country Status (1)

Country Link
WO (1) WO2014195849A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843073A (en) * 1986-06-25 1989-06-27 Farmitalia Carlo Erba S.P.A. 1-t-butyl ergolines useful in the treatment of cerebral insufficiency and senile dementia
US4870179A (en) * 1984-08-07 1989-09-26 Inverni Della Beffa Spa Process for preparing lysergol derivatives
US4980475A (en) * 1984-03-27 1990-12-25 I D B Holding S.P.A. Process for the preparation of N-10 alpha-methoxyl-lumilysergol and esters, thereof, and intermediates for their preparation
US20070060604A1 (en) * 2002-03-25 2007-03-15 Council Of Scientific And Industrial Research Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980475A (en) * 1984-03-27 1990-12-25 I D B Holding S.P.A. Process for the preparation of N-10 alpha-methoxyl-lumilysergol and esters, thereof, and intermediates for their preparation
US4870179A (en) * 1984-08-07 1989-09-26 Inverni Della Beffa Spa Process for preparing lysergol derivatives
US4843073A (en) * 1986-06-25 1989-06-27 Farmitalia Carlo Erba S.P.A. 1-t-butyl ergolines useful in the treatment of cerebral insufficiency and senile dementia
US20070060604A1 (en) * 2002-03-25 2007-03-15 Council Of Scientific And Industrial Research Antibiotic pharmaceutical composition with lysergol as bio-enhancer and method of treatment

Also Published As

Publication number Publication date
WO2014195849A2 (fr) 2014-12-11

Similar Documents

Publication Publication Date Title
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
WO2014174425A3 (fr) Compositions et méthodes de traitement de l'orthostasie et de maladies neurologiques
WO2013175376A3 (fr) Compositions et méthodes de traitement de la douleur locale
MX386467B (es) Composiciones y métodos para el tratamiento de xerostomia (sequedad bucal)
WO2014068463A3 (fr) Compositions et procédés de traitement d'une inflammation et de troubles métaboliques
WO2014091384A3 (fr) Compositions et méthodes pour le traitement de la mucosite
WO2016046680A3 (fr) Compositions et procédés de traitement de maladies métaboliques hépatiques
MX2022005523A (es) Composiciones y metodos para el tratamiento de infecciones fungicas.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2013175359A3 (fr) Compositions et méthodes pour le traitement de la sclérose en plaques
WO2014087323A3 (fr) Compositions et procédés pour le traitement de maladies auto-immunes et métaboliques chroniques
WO2014006529A3 (fr) Compositions et méthodes de traitement de la douleur modérée à aiguë
WO2013167998A3 (fr) Compositions et méthodes de traitement de troubles autonomiques et autres troubles neurologiques
MX383090B (es) Composiciones y métodos para el tratamiento de enfermedades infecciosas orales.
WO2014097137A3 (fr) Compositions et méthodes destinées à traiter les avc et autres maladies neurologiques
WO2014195850A3 (fr) Compositions et méthodes de traitement de maladies neurologiques et de troubles neurologiques
WO2014195849A3 (fr) Composition et méthodes de traitement de maladies cérébrovasculaires
WO2015028976A3 (fr) Composés et méthodes de traitement de maladies inflammatoires
WO2013175344A3 (fr) Compositions et méthodes pour le traitement de la parodontite et de la polyarthrite rhumatoïde
WO2013167989A3 (fr) Compositions et méthodes de traitement de troubles neurologiques
MX386208B (es) Composiciones y métodos para el tratamiento de pólipos gastrointestinales.
WO2014118649A3 (fr) Compositions et méthodes pour le traitement de maladies cardiovasculaires
WO2017208088A3 (fr) Compositions et méthodes pour le traitement de la maladie de parkinson

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14807680

Country of ref document: EP

Kind code of ref document: A2